About us

  • The Assay Development and Screening Platform (ADSP) has been established in 2010 as a Research Group within the Institute of Molecular Toxicology and Pharmacology.

    In collaboration with researchers of the Helmholtz Zentrum München as well as national and international cooperation partners, custom-designed assays are developed and/or optimized to screen for new bioactive molecules. Here, a major focus is devoted to the development of phenotypic assays for High-Content Screening (HCS) approaches in order to better reflect the biology of the underlying disease state. For this purpose, ADSP provides state-of-the-art equipment as well as screening techniques and maintains a chemical compound collection including a diversity set of compounds and the Prestwick FDA approved drugs. In order to evaluate and manage the screening data, ADSP uses IDBS ActivityBase together with PerkinElmer Columbus, Spotfire and High-Content Profiler.

    Research projects of ADSP deal with the identification of new targets and small molecule modulators of Ubiquitin singling processes implicated in immune response, cancer development and DNA repair.

We use cookies to improve your experience on our Website. We need cookies to continuously improve the services, to enable certain features and when embedding services or content of third parties, such as video player. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.